Palvella Therapeutics Inc (PVLA)

Apr 07, 2025

Palvella CEO to Present at Healthcare Innovation Conference - MSN

Apr 07, 2025

Apr 05, 2025

Q1 EPS Estimate for Palvella Therapeutics Lowered by Analyst - Defense World

Apr 05, 2025

Apr 04, 2025

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire

Apr 04, 2025

Apr 04, 2025

Rare Disease Breakthrough: Palvella CEO Reveals Growth Strategy at Major Healthcare Conference - Stock Titan

Apr 04, 2025

Apr 03, 2025

Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN

Apr 03, 2025

Apr 02, 2025

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times

Apr 02, 2025

Apr 02, 2025

Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan

Apr 02, 2025

Apr 02, 2025

Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World

Apr 02, 2025

Apr 02, 2025

Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo

Apr 02, 2025

Apr 01, 2025

Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey

Apr 01, 2025

Apr 01, 2025

Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank - The Globe and Mail

Apr 01, 2025

Mar 31, 2025

Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com

Mar 31, 2025

Mar 31, 2025

Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com

Mar 31, 2025

Mar 31, 2025

Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025

Mar 31, 2025

Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 31, 2025

Mar 31, 2025

PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 31, 2025

Mar 30, 2025

Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN

Mar 30, 2025

Mar 29, 2025

Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World

Mar 29, 2025

Mar 28, 2025

Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView

Mar 28, 2025

Mar 28, 2025

Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World

Mar 28, 2025

Mar 28, 2025

Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat

Mar 28, 2025

Mar 27, 2025

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World

Mar 27, 2025

Mar 27, 2025

Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Insider Monkey

Mar 27, 2025

Mar 26, 2025

Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq

Mar 26, 2025

Mar 26, 2025

Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - MarketScreener

Mar 26, 2025

Mar 26, 2025

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading - Defense World

Mar 26, 2025

Mar 26, 2025

Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 25, 2025

Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq

Mar 25, 2025

Mar 25, 2025

Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada

Mar 25, 2025

Mar 25, 2025

Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com

Mar 25, 2025

Mar 25, 2025

Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com

Mar 25, 2025

Mar 25, 2025

Palvella Therapeutics initiated with a Buy at Stifel - TipRanks

Mar 25, 2025

Mar 20, 2025

Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025

Mar 19, 2025

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail

Mar 19, 2025

Mar 18, 2025

Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq

Mar 18, 2025

Mar 18, 2025

Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan

Mar 18, 2025

Mar 18, 2025

Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK

Mar 18, 2025

Mar 16, 2025

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance

Mar 16, 2025

Mar 16, 2025

Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st

Mar 16, 2025

Mar 12, 2025

Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com

Mar 12, 2025

Mar 12, 2025

PavellaUndiscovered Biotechnology Stock - TradingView

Mar 12, 2025

Mar 12, 2025

PalvellaUndiscovered Biotechnology Stock - Barchart

Mar 12, 2025

Mar 09, 2025

Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World

Mar 09, 2025

Mar 08, 2025

Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025

Mar 07, 2025

Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com

Mar 07, 2025

Mar 07, 2025

Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK

Mar 07, 2025